European STOXX Europe 600 Index ended the week broadly flat amid stalled geopolitical negotiations and fluctuating oil prices, investors are keenly observing potential opportunities in undervalued ...

The contract is awarded for products that bring improvement to the healthcare industry.Coloplast, a global medical device company and market ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Coloplast is a global leader in specialized intimate healthcare, with strong innovation, high margins, and a defensible moat in core segments. Despite a 20% share price drop, I see upside potential, ...

Coloplast announced it will acquire wound care product company Kerecis for $1.3 billion. The acquisition will give Coloplast an opportunity to “strategically strengthen [its] presence in the advanced ...

The new intermittent catheter Luja™ addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole ...

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...

Coloplast (CLPBY) faces operational challenges, with four consecutive top-line misses and reduced growth expectations, but retains a strong core franchise. CLPBY's CEO search remains unresolved, and ...

Coloplast revises the financial guidance on organic growth and EBIT growth in constant currencies before special items for FY 2025/26, ...